NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.

The Cambridge, Mass.-based firm said that the goal of the collaboration is to prospectively identify specific genomic alterations in each patient's tumor. The results would be used for patient stratification, for guiding further drug development, and potentially for the commercialization of molecular diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.